Overactive bladder
Conditions
Interventions
After completion of the initial assessment, oral vibegron will be started. After at least 12 weeks of treatment, patients will be re-evaluated, and if the OABSS has improved by 3 or more points, disco
Sponsors
Sapporo Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patients with overactive bladder (OABSS total score 3 or more and question 3 score 2 or more) Patients who are newly initiated on vibegron for OAB Patients who have provided informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Patients who are minors or who lack the capacity to provide consent Patients with a history of prior pharmacological treatment for OAB (e.g. anticholinergic agents, beta3-adrenergic agonists, intravesical botulinum toxin injection therapy, sacral neuromodulation, magnetic stimulation therapy, etc.) Patients managed with intermittent catheterization or an indwelling urethral catheter Patients with active cystitis (eligible after appropriate treatment) Any other patients deemed inappropriate for inclusion by the treating physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| discontinuation maintenance rate at 4 weeks after drug withdrawal | — |
Secondary
| Measure | Time frame |
|---|---|
| discontinuation maintenance rate at 12 weeks after treatment discontinuation, percentage change in IPSS and OABSS, time to resumption of medication, incidence of adverse events | — |
Countries
Japan
Contacts
Public ContactYuki Kyoda
Sapporo Medical University Department of Urology
Outcome results
None listed